In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.

Subcategories:Axial SpondyloarthritisGout and Crystalline ArthritisGuidelinesMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis
In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.
A EULAR 2022 abstract session looked at several studies that seek to increase understanding of RA pathogenesis & identify patients at risk for disease progression.
Dr. Jacob van Laar took a deep dive into the what defines difficult-to-treat rheumatoid arthritis & how to approach these patients during EULAR 2022.
This EULAR 2022 session emphasized the importance of recognizing the axial manifestations of psoriatic arthritis and treating these symptoms accordingly.
A study from Haibel et al. in patients with chronic knee arthritis found intra-articular morphine did not lead to a significant, short-term reduction in pain compared with placebo and proved inferior to treatment with intra-articular triamcinolone.
EULAR 2022 (VIRTUAL)—The pace of scientific progress in research medicine is incredible and seems to only accelerate with time. Thus, the 2022 Congress of the European Alliance of Associations for Rheumatology (EULAR) session on late-breaking abstracts fittingly captured the excitement and timeliness of a number of research projects that have just recently been completed and…
In this EULAR 2022 session, new & revised treatment recommendations for ANCA-associated vasculitis, axial spondyloarthritis & rheumatoid arthritis were presented.
Fazila Aseem, MD, MPH, Alexander D. Jeffs, MD, Enid Y. Sun, MD, MPH, Randaline R. Barnett, MD, Courtney Blodgett, AG-ACNP, Winnie Lau, MD, Casey Olm-Shipman, MD, MS, Matthew F. Sharrock, MD, Rhonda Cadena, MD, Yueh. Z. Lee, MD, PhD, Alfredo C. Rivadeneira, MD, & Clio A. Rubinos, MD, MS |
Scleromyxedema is a primary cutaneous mucinosis characterized by a diffuse and generalized papular skin eruption of mucinous deposits throughout the upper dermis. In addition to dermatologic manifestations, scleromyxedema may involve the cardiopulmonary, gastrointestinal, renal and nervous systems. Dermato-neuro syndrome (DNS) is a rare, severe neurologic complication of scleromyxedema.1,2 The pathogenesis of DNS is unknown, but…
Ryan Guerrettaz, MD, Angelo Ciliberti, MD, Rochella Ostrowski, MD, Elise Wolff, DO, Nadia Qureshi, MD, & Ramzan Shahid, MD |
Acute febrile neutrophilic dermatosis, or Sweet syndrome, is an inflammatory disease that classically presents with fever, leukocytosis and tender, erythematous plaques characterized by neutrophilic infiltrates on biopsy. Sweet syndrome has been reported in association with several autoimmune diseases, including inflammatory bowel disease, systemic lupus erythematous, rheumatoid arthritis and sarcoidosis.1 Here, we discuss a case of…
Hala Fadhil Hasan, MBChB; Featured Image from Middle East & North Africa |
Rheumatic Diseases of Childhood: Juvenile Dermatomyositis with Calcinosis Cutis These images depict a 14-year-old boy with a two-year history of proximal muscle weakness affecting both upper and lower limbs, and a skin rash affecting his face. He was diagnosed with juvenile dermatomyositis and developed calcinosis over both legs with skin infection and ulceration. Plain X-ray…